H Lundbeck A/S (OTCMKTS:HLUYY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The brokerage presently has a $62.00 price objective on the stock. Zacks Investment Research‘s price target points to a potential upside of 10.22% from the stock’s previous close.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Separately, Deutsche Bank AG downgraded H Lundbeck A/S from a “hold” rating to a “sell” rating in a research note on Friday, July 28th.
H Lundbeck A/S (OTCMKTS HLUYY) opened at $56.25 on Wednesday. The stock has a market capitalization of $10,869.62, a price-to-earnings ratio of 25.30, a PEG ratio of 1.08 and a beta of 0.27. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.93 and a current ratio of 1.21. H Lundbeck A/S has a one year low of $37.21 and a one year high of $66.67.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://weekherald.com/2017/11/15/h-lundbeck-as-hluyy-stock-rating-upgraded-by-zacks-investment-research.html.
About H Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
Receive News & Ratings for H Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.